Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Ablation of canine prostate using two-stage intraprostatic hot agarose solution and enzyme injection

Abstract

Enzyme ablation of the hyperplastic prostate may be an ideal method of management of BPH. However, the unsatisfactory ablation affects in vivo contrast with successful in vitro results limiting the enthusiasm for further research. In this study, we make efforts to solve the problems in the use of enzyme ablation of BPH in vivo and to measure satisfactory effect.

Material and methods: A total of 18 hybrid dogs between the ages of 7 and 11 y underwent this experiment. Eight dogs were divided into four groups according to the injection formula: enzyme solution, hot D-Hanks' plus enzyme solution, hot agarose plus enzyme solution, and hot agarose solution alone. After selecting the agarose plus enzyme solution group in the first month, the remainder 10 dogs were treated with this two-stage method. Intravenous or oral antibiotics were administered perioperatively. All operations were performed directly by way of laparotomy. The prostates were observed and harvested with surrounding tissue at 24 hrs, 7 days, 14 days, 1 month and 3–5 months after treatment. Gross and microscopic examinations were performed.

Results: Only agarose plus enzyme group shows obvious cavity formation with concomitant size reduction and softening of the prostate ablation effect in the four groups. At 24 h after injection, the prostates demonstrated cavity formation containing liquefied necrotic tissue. The liquefied tissue was absorbed in 7–14 days. At 1 month, the size of most prostates decreased with a corresponding decrease in the size of the cavities. The cavities nearly disappeared within 3–5 months, and the size of prostates decreased to between 1/2 and 1/4 of the pretreatment sizes. All prostates had intact urethral mucosa and capsule. No complications directly related to enzyme ablation were identified. In the control groups there were no significant cavities or decrease in prostate size.

Conclusions: This two-stage thermal and enzyme ablative method can significantly ablate prostate tissue without identifiable complications, and would be possibly applied to treating human BPH in the future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Mecust WK et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141: 243–247.

    Article  Google Scholar 

  2. Zlotta AR, Djavan B . Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data. Curr Opin Urol 2002; 12: 7–14.

    Article  Google Scholar 

  3. Savoca G et al. Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: preliminary report. Eur Urol 2001; 40: 504–508.

    Article  CAS  Google Scholar 

  4. Goya N et al. Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J Urol 1999; 162: 383–386.

    Article  CAS  Google Scholar 

  5. DiTrolio J, Patel P, Watson RA, Irwin Jr RJ . Chemo-ablation of the prostate with dehydrated alcohol for the treatment of prostatic obstruction. J Urol 2002; 167: 2100–2104.

    Article  CAS  Google Scholar 

  6. Plante MK, Gros AL, Kliment J, Kida M . Zvara: intraprostatic ethanol chemoablation via transurethral and transperineal injection. BJU Int 2003; 91: 94–98.

    Article  CAS  Google Scholar 

  7. Harmon WJ, Barrett DM, Qian J . Transurethral enzymatic ablation of the prostate: canine model. Urology 1996; 48: 229–233.

    Article  CAS  Google Scholar 

  8. Darson MF, Barrett DM . Transurethral enzyme injection—future management of benign prostatic hyperplasia. Mayo Clin Proc 1998; 73: 908–911.

    Article  CAS  Google Scholar 

  9. Gocken M, Guy TJ . Composition and method for treating benign prostatic hyperplasia. United States Patent 5, 116, 615. May 26 1992.

  10. Steiner MS, Couch RC, Raghow S, Stauffer D . The chimpanzee as a model of human benign prostatic hyperplasia. J Urol. 1999; 162: 1454–1461.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Antolak, Stanley Jr J, M.D. for kindly revising the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, C., Wang, L., Shong, C. et al. Ablation of canine prostate using two-stage intraprostatic hot agarose solution and enzyme injection. Prostate Cancer Prostatic Dis 7, 316–320 (2004). https://doi.org/10.1038/sj.pcan.4500748

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500748

Keywords

Search

Quick links